V. Subbiah
Molecular Biology · 2015–2023
A researcher in the Science corpus: 7 papers; trusts 6 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 18 citations into it
- Genetics — 8 citations into it
- Statistics and Probability — 8 citations into it
- Radiology, Nuclear Medicine and Imaging — 6 citations into it
- Health Informatics — 5 citations into it
- Neurology — 5 citations into it
Whom V. Subbiah trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from V. Subbiah's perspective
Ordered by how strongly the researchers V. Subbiah trusts endorse each paper. Same corpus, a different order for every researcher.
- Digital twins to personalize medicine (Genome Medicine)
- Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension
- The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? (Personalized Medicine)
- Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm (Nature Biotechnology)
- Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation (New England Journal of Medicine)
- A Review of Generalizability and Transportability (Annual Review of Statistics and Its Application)
- Translational research: Crossing the valley of death (Nature)
- Applications of continual learning machine learning in clinical practice
- Key challenges for delivering clinical impact with artificial intelligence
- Adversarial attacks on medical machine learning (Science)
Their papers
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (2015) — 1,621 citations
- The next generation of evidence-based medicine (2023) — 438 citations
- Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial (2022)
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial (2022)
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) — 1,555 citations
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers (2020) — 604 citations
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. (2018) — 745 citations